Magnetically-stimulated transformations in the nanostructure of PEGylated phytantriol-based nanoparticles for on-demand drug release

Colloids Surf B Biointerfaces. 2021 Nov:207:112005. doi: 10.1016/j.colsurfb.2021.112005. Epub 2021 Jul 26.

Abstract

Lipid-based liquid crystalline (LLC) systems are formed by the self-assembly of lipid materials in aqueous environments. The internal nanostructures of LLC systems can be manipulated using remote stimuli and have the potential to serve as 'on-demand' drug delivery systems. In this study, a magnetically-responsive system that displayed a transition in nanostructure from liposomes to cubosomes/hexasomes under external alternating magnetic field (AMF) was established by the incorporation of iron oxide nanoparticles (IONPs) into a PEGylated phytantriol (PHYT)-based LLC system. Small angle X-ray scattering (SAXS) was utilized to assess the equilibrium phase behaviour of the systems with different compositions of the lipids to find the optimized formulation. Time-resolved SAXS was then used to determine the dynamic transformation of nanostructures of the IONP-containing systems with the activation of AMF. The formulation containing PHYT and DSPE-PEG2000 at a 95 to 5 molar percent ratio produced a transition from lamellar phase to bicontinuous cubic phase, showing a slow-to-fast drug release profile. Inclusion of either 5 nm or 15 nm IONPs imparted magnetic-responsiveness to the system. The magnetically-responsive system produced an 'on-demand' drug delivery system from which the drug release was able to be triggered externally by AMF-stimulation.

Keywords: Lipid-based formulation; Liquid crystalline nanostructure; Magnetically-activated; PEGylated liposomes; ‘On-demand’ drug release.

MeSH terms

  • Drug Liberation
  • Fatty Alcohols
  • Nanoparticles*
  • Nanostructures*
  • Pharmaceutical Preparations*
  • Polyethylene Glycols
  • Scattering, Small Angle
  • X-Ray Diffraction

Substances

  • Fatty Alcohols
  • Pharmaceutical Preparations
  • Polyethylene Glycols
  • 3,7,11,15-tetramethyl-1,2,3-hexadecanetriol